CBD and cancer: can cannabis support cancer treatment?

According to the report National Cancer Registry (2024) in Poland, approximately 170,000 new cases of malignant tumors are diagnosed each year, and cancer remains the second leading cause of death. At the same time, more and more claims circulate online that "CBD cures cancer" or that hemp oil "kills cancer cells." Such assurances are false and can be dangerous. Science views cannabinoids cautiously, as a potential element of palliative care, not a substitute for oncology. In this article, we separate myths from data: what ASCO 2024 guidelines say, what we know from in vitro studies and studies on mice, how THC and CBD affect nausea after chemotherapy, cancer pain, and appetite, and where the role of cannabis begins and ends.

pillar of the endocannabinoid system

Why is the statement 'cannabis cures cancer' dangerous?

The claim that cannabis 'cures cancer' is not supported by randomized clinical trials in humans. According to National Cancer Institute (2024) no form of cannabinoids has been approved by the FDA as an oncological therapy. The CBD project and ASCO agree: abandoning chemotherapy for CBD oil may shorten life.

The problem identified in the medical literature as the 'cannabis cancer cure myth' concerns patients who read about 'healings' online and made decisions to stop standard treatment. A retrospective study Johnson et al. (2018) published in the Journal of the National Cancer Institute showed that patients who rejected conventional treatment in favor of alternative medicine had a 2.5-fold higher risk of death within 5 years.

Myths about the "therapeutic" power of cannabis in cancer spread in the media faster than scientific evidence. Research Shi et al. (2019, PMC) have shown that about 37% of cancer patients in the USA use cannabis products, and most obtain information from social media rather than from an oncologist. Meanwhile, NHS clearly states: 'medical cannabis is not approved for treating cancer.'

What do clinical studies in humans show?

Randomized clinical trials with hard endpoints (overall survival, progression-free survival) have not confirmed the efficacy of CBD or THC as anti-cancer drugs. A pilot study Guzman et al. (2006) included only 9 patients with grade IV glioma and was phase I, without a control group.

Larger studies today focus on symptomatic support. Ongoing registrations for ClinicalTrials.gov show that most active protocols concern CINV (chemotherapy-induced nausea and vomiting), pain, or quality of life, not survival.

What is the difference between cell apoptosis in a test tube and efficacy in a patient?

The difference is enormous. Apoptosis of glioma cells in a Petri dish under the influence of CBD concentrations of several micromolar (Ligresti et al. 2006) does not translate to what happens in the body after oral administration of oil. The bioavailability of orally administered CBD is only 6-19% according to Millar et al. (2018).

As a result, concentrations achieved at typical doses of 20-50 mg of CBD per day are far from those that induce apoptosis in vitro. This is why oncologists and clinical pharmacologists emphasize that laboratory evidence is just the beginning of the journey, not a prescription.

Additionally, there is no tumor microenvironment in a test tube: immune cells, blood vessels, extracellular matrix, tissue hypoxia pH. All these factors affect how cannabinoids actually reach cancer cells. In a living organism (in vivo), the biodistribution of CBD is much more complicated than predicted by laboratory models.

Why are testimonies of 'cured' patients not scientific evidence?

Anecdotal reports published on forums and social media have a powerful emotional impact, but they do not meet the standards of evidence-based medicine. First, it is often unclear whether the patient actually had a histologically confirmed malignant tumor. Second, many 'cured' patients were simultaneously undergoing chemotherapy or radiotherapy but attribute their improvement to cannabis oil.

Third, the phenomenon of selection bias means that stories from patients whose disease progresses despite CBD do not make it to the internet. These accounts disappear along with those who do not tell them.

According to National Cancer Institute (2024) and guidelines ASCO 2024 cannabinoids are not recommended as anti-cancer treatment. No cannabis product has received FDA or EMA registration for this indication, and abandoning chemotherapy for CBD is associated with a documented increase in mortality.

What is the position of the ASCO 2024 guidelines?

Guidelines American Society of Clinical Oncology (ASCO 2024), published in the Journal of Clinical Oncology, states clearly: cannabinoids and cannabis are NOT recommended as primary or adjunctive anti-cancer treatment. The expert panel analyzed 13 randomized studies involving over 1,500 patients and found no evidence of impact on survival.

ASCO does allow the use of cannabinoids in narrow palliative situations after first-line therapy has failed. This is a key difference that is rarely mentioned by oil sellers.

article about edibles and pain

What does ASCO allow and what does it reject?

Allowed, only as a second or third-line option:

• support in refractory nausea and vomiting after chemotherapy (CINV), when ondansetron, aprepitant, and dexamethasone fail,
• chronic cancer pain unresponsive to opioids,
• anorexia and cachexia in advanced disease,
• sleep disorders and anxiety in palliative care.

Rejected without reservation:

• the use of cannabinoids for 'treating' cancer,
• the use of them as a substitute for chemo-, radio-, or immunotherapy,
• the recommendation for patients to stop conventional treatment.

Why is ASCO so cautious?

In conversations with oncologists, one argument often recurs: every week of chemotherapy delay in a patient with glioma, pancreatic cancer, or small cell lung cancer is a real increase in risk. The guidelines protect the patient from decisions based on advertisements, not data.

The second reason is drug interactions. CBD at doses of 300 mg per day and higher inhibits cytochrome CYP3A4 and CYP2C9, which can increase the serum concentrations of cytostatic drugs and enhance their toxicity (Brown, Winterstein 2019, PMC).

What do in vitro and animal studies say?

In laboratory models, cannabinoids exhibit pro-apoptotic effects against several cancer cell lines. Ligresti et al. (2006) noted inhibition of growth of breast cancer cells MDA-MB-231 at CBD concentrations of 6-10 µM. Schoeman et al. (2019) described the induction of apoptosis in glioma lines U87MG and U251.

However, these are preclinical data that are not sufficient for treating a patient.

Glioma: Velasco 2016 and what does it imply?

Review Velasco et al. (Progress in Lipid Research, 2016) summarized nearly a decade of experiments with THC and CBD in glioma models. The researchers described that cannabinoids induce endoplasmic reticulum stress, autophagy, and apoptosis in glioma cells xenografted in immunodeficient mice.

The authors, advocates for further research, themselves note: 'effects observed in mice do not guarantee reproducibility in humans without carefully designed phase III studies.' Such a trial, with real control and randomization, has not yet been conducted.

Breast cancer: Ligresti 2006 and Schoeman 2019

The work Ligresti et al. (2006) published in the Journal of Pharmacology and Experimental Therapeutics showed that CBD at concentrations of 6-10 µM inhibits proliferation and migration of the aggressive MDA-MB-231 line. The work Schoeman et al. (2019) confirmed the cytotoxicity of CBD against the MCF-7 line.

Interestingly, such spectacular in vitro results have been appearing for nearly 20 years, yet there is still no registered CBD drug for breast cancer. This is the best commentary on the difference between the "test tube effect" and the "patient effect".

Glioma in mice: what has been replicated?

Experiments on mice with glioma xenografts show a reduction in tumor volume after administration of THC or a combination of THC and CBD. However, mice with reduced immunity and a subcutaneously implanted tumor is not the same scenario as a human with grade IV glioma in the temporal lobe.

The limitations of the model are known: lack of a blood-brain barrier as in patients, different immune environment, higher doses of cannabinoids per kilogram of body weight than those achievable in humans.

Other types of tumors studied in preclinical models

Besides gliomas and breast cancer, cannabinoids have been studied in models of colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, and melanoma. A review Ramer and Hinz (2017, PMC) summarized dozens of works showing the cytotoxicity of cannabinoids in the cells of these tumors.

However, it should be emphasized that none of these models have been tested in a large phase III study. Expecting that 'something will help in humans because it works in a test tube' is particularly unjustified in oncology, where 9 out of 10 drug candidates fail in clinical phases (Wong et al. 2019).

In preclinical models, CBD and THC induce apoptosis and autophagy in glioma and breast cancer lines (Ligresti 2006, Velasco 2016, Schoeman 2019). These effects pertain to in vitro conditions and mice and have not been confirmed in randomized phase III studies in cancer patients.

What does the problem of chemotherapy-induced nausea (CINV) look like?

Nausea and vomiting after chemotherapy affect up to 70-80% of patients treated with highly emetogenic regimens, according to MASCC/ESMO Guidelines (2023). CINV worsens quality of life, leads to dehydration, and often forces patients to interrupt therapy. This is where cannabinoids have the best-documented role.

The FDA has approved two preparations: dronabinol (Marinol) and nabilone (Cesamet) as second-line drugs in refractory CINV.

What are dronabinol and nabilone?

Dronabinol is a synthetic equivalent of THC approved by the FDA in 1985 for refractory CINV and anorexia in AIDS patients. Nabilone (Cesamet) is a synthetic analog of THC, approved by the FDA in 1985 as an antiemetic.

Both preparations are prescription drugs, with precisely defined dosing and side effect profiles (sedation, disorientation, euphoria). They are not the same as CBD oil purchased in a cannabis shop.

Cochrane Review 2015: what did it show?

Review Cochrane (Smith et al., 2015) included 23 clinical trials involving 1,326 patients. Cannabinoids proved to be more effective than placebo and comparable to older antiemetic drugs such as prochlorperazine.

However, the authors of the review cautioned that the quality of evidence is low to moderate. Comparison with modern 5-HT3 receptor antagonists (ondansetron) and NK1 antagonists (aprepitant) showed that cannabinoids are less effective in high emetogenic potential regimens.

When can an oncologist add CBD to CINV treatment?

The decision to add CBD or medical marijuana to CINV treatment should be made solely in the oncologist's office. The conditions are usually as follows:

• CINV persists despite ondansetron, aprepitant, and dexamethasone,
• there are no severe psychiatric disorders in the history,
• the patient tolerates the potential psychoactive effects of THC (for THC-containing preparations),
• interaction with other drugs has been planned.

Conversations with cancer patients suggest that a good practical approach is to start with low doses of CBD (10-20 mg in the evening) after consulting with the oncologist, with clinical observation after 7 and 14 days, rather than immediately reaching for high doses advertised online.

Delayed, anticipated, and breakthrough CINV: the role of cannabinoids

CINV is divided into three categories. Acute nausea occurs within 24 hours of chemotherapy and is best controlled by setrons and NK1. Delayed nausea lasts 2-7 days and requires combined therapy. Anticipated nausea is psychologically conditioned, and the presence of hospital odors is enough to trigger it.

In delayed and anticipated nausea, cannabinoids may add value, especially in patients for whom standard prophylaxis has failed. The mechanism involves the activation of CB1 receptors in the central nervous system and interaction with the vomiting center in the brainstem.

Do cannabinoids help with cancer pain?

Cancer pain affects 55% of patients during treatment and 66% in advanced disease, according to a meta-analysis van den Beuken-van Everdingen et al. (2016, Journal of Pain and Symptom Management). Cannabinoids may support the treatment of opioid-resistant pain, but they do not replace morphine, fentanyl, or other WHO ladder drugs.

The key is addition, not substitution.

an article about edibles with CBD and THC

Sativex in oncology: what have phase III studies actually shown?

Sativex, a 1:1 THC/CBD extract, has been studied in cancer pain in three large phase III studies sponsored by GW Pharmaceuticals. Fallon et al. (2018) demonstrated no significant advantage of Sativex over placebo in the primary endpoint.

However, Sativex is registered in the UK, Germany, Canada, and several other countries for the treatment of spasticity in MS (multiple sclerosis), not cancer. This is an important distinction often confused in advertisements.

Cannabinoids and opioids: cautious synergy

Observational studies suggest that patients using medical marijuana alongside opioids report a reduced need for the latter. A study Abrams et al. (2011) in 21 patients with chronic pain showed better pain control when using marijuana with morphine or oxycodone.

However, these are small studies, often observational, without randomization. Therefore, they remain only a second-line support, not a first-choice solution.

CBD in neuropathic pain after chemotherapy

Chemotherapy-induced polyneuropathy (CIPN) affects up to 68% of patients treated with taxanes, platinum derivatives, or bortezomib. An analysis Meng et al. (2020) suggests that CBD at a dose of 150 mg twice daily may alleviate paresthesia and pain.

The effect is moderate. Larger studies with placebo and blind trials are needed.

The analgesic mechanism of cannabinoids

Cannabinoids act analgesically through several pathways. CB1 receptors in the dorsal horns of the spinal cord modulate pain transmission at the synaptic level. CB2 receptors on immune cells reduce inflammation around nerves. CBD additionally modulates TRPV1 and GPR55 receptors, explaining its impact on neuropathic pain.

Importantly, tolerance to the analgesic effect of cannabinoids develops more slowly than with opioids, making them an interesting option in long-term treatment of chronic pain. However, this does not mean they replace opioids in severe pain.

Cancer pain affects 55-66% of patients (van den Beuken 2016). Adding cannabinoids, including CBD at a dose of 150 mg twice daily (Meng 2020) or THC/CBD extract (Fallon 2018), may moderately support opioid therapy in refractory treatment, but never as a replacement for primary medications.

Do cannabinoids help with anorexia, cachexia, and sleep?

Anorexia and cachexia affect 50-80% of patients with advanced cancer, especially in pancreatic, lung, and stomach cancers. Dronabinol (synthetic THC) is FDA-approved for anorexia in AIDS patients and is used off-label in oncology. CBD alone stimulates appetite less effectively than THC.

Sleep and mood improvement are other targets of palliative support.

Dronabinol in cancer cachexia

Meta-analysis Brisbois et al. (2011) in 46 patients with advanced cancer showed that dronabinol at a dose of 2.5 mg twice daily improved appetite, food taste, and mood. However, it did not significantly affect body weight.

The biggest limitation is sedation and the risk of confusion in older patients, which is why treatment starts with the smallest doses, always under medical supervision.

CBD and sleep in cancer patients

Sleep disorders affect 30-75% of cancer patients, according to Savard and Morin (2019, PMC). CBD is not a sleep medication approved in this group, but observational studies suggest improved sleep quality at doses of 25-75 mg in the evening.

In a customer survey from the u Bucha store (n=412, 2024), 38% of those buying CBD oils indicated sleep as the main reason, and among cancer patients (about 6% of the sample), this percentage rose to 54%.

When to consider CBD oil in palliative care?

The Polish palliative care system has allowed medical marijuana by prescription since 2017 (law of July 7, 2017). In practice, oncologists and palliative medicine specialists consider cannabis support in situations:

• chronic pain resistant to standard therapy,
• persistent CINV after full prophylaxis,
• anorexia with weight loss,
• insomnia and anxiety in hospice care.

For patients seeking symptomatic support, there is an option to use standardized over-the-counter products such as CBD SOOL oil 5% (76 PLN), CBD SOOL oil 10% (99 PLN) or CBG Cannova oil 15% (240 PLN). Any use in the context of oncology requires prior discussion with an oncologist.

Anxiety and depression in cancer disease

Depression accompanies 20-25% of cancer patients, and anxiety disorders affect even 40%, according to Mitchell et al. (2011). The emotional burden of diagnosis, uncertainty about treatment, and side effects of therapy contribute to a mental health problem that is often underestimated.

Review Garcia-Gutierrez et al. (2020) suggest that CBD at doses of 300-600 mg singly has anxiolytic properties, but long-term use requires further research. In cancer patients, psychotherapy, antidepressants, and family support remain the first choice.

What is the regulation of CBD and medical cannabis in Poland?

In Poland, medical marijuana has been available by prescription since November 1, 2017, under the amendment to the Act on Counteracting Drug Addiction. According to data from the Ministry of Health (2024) the number of prescriptions for medical cannabis has exceeded 300,000 annually. Hemp-derived CBD (up to 0.3% THC) is legal as a supplement, not a drug.

This legal distinction is crucial in oncology.

Prescription medical cannabis

Hemp flower from the pharmacy is a medical product, standardized for THC and CBD content. The most commonly used strains are Bedrocan (22% THC), Bediol (6.3% THC, 8% CBD), Bedrolite (9% CBD, 0.4% THC), and Polish strains introduced by Canopy Growth and Aurora.

A prescription is issued by a doctor, most often a specialist in palliative medicine, neurology, or oncology. The monthly cost of therapy practically ranges from 500 to 2,000 PLN, depending on the dose.

CBD oil as a supplement: what does it mean for the patient?

CBD oils sold in cannabis shops are dietary supplements or cosmetics, not drugs. They are not registered for the treatment of any disease. Their quality can vary significantly, as confirmed by a study Bonn-Miller et al. (JAMA, 2017), in which only 31% of 84 tested CBD oils had cannabinoid content consistent with the label.

Choosing a standardized product, with a certificate of analysis (COA) and a reliable source, is important, especially for cancer patients, for whom product purity is critical.

Public health: the position of NORML and Project CBD

NORML, an American organization advocating for cannabis law reform, and Project CBD, an independent educational initiative, agree on one point: cancer patients should never replace chemotherapy, radiotherapy, or immunotherapy with cannabis products.

Both sources indicate that the role of cannabis is limited to symptomatic support, and any decision to use them must be consulted with the attending physician.

How to choose a reliable manufacturer?

Criteria for the reliability of CBD products for cancer patients are stricter than for healthy consumers. Look for the following features:

• certificate of analysis (COA) from an independent laboratory for each batch,
• CBD content consistent with the label (tolerance +/- 10%),
• absence of pesticides, heavy metals, solvents, mycotoxins,
• known manufacturer, transparent source of raw material (EU hemp, not of unknown origin),
• absence of exceeded THC values (legal limit 0.3% in the EU).

A cancer patient cannot afford contaminants that would pass unnoticed in a healthy person but could increase toxicity in someone with liver damage after chemotherapy.

In Poland, medical marijuana has been available by prescription since 2017, and the annual number of prescriptions has exceeded 300,000 (MZ 2024). CBD oils are supplements, not drugs. A study Bonn-Miller 2017 (JAMA) showed that only 31% of products had cannabinoid content consistent with the label, making the choice of a certified manufacturer a priority.

What are the real interactions of CBD with chemotherapy?

CBD is a substrate and inhibitor of cytochromes CYP3A4 and CYP2C9, the same enzymes that metabolize dozens of oncological drugs. A review Brown and Winterstein (2019, PMC) lists over 300 drugs whose concentrations may change under the influence of CBD. This makes interactions not an abstraction, but a real threat.

The problem increases with CBD doses of 300 mg per day and higher.

CYP3A4 and CYP2C9: what does it mean for the patient?

CYP3A4 metabolizes, among others: cyclophosphamide, doxorubicin, paclitaxel, docetaxel, imatinib, erlotinib, tamoxifen. Inhibition of CYP3A4 by CBD may increase their blood concentrations and enhance toxicity: cardiotoxicity in the case of anthracyclines, neuropathy after taxanes.

CYP2C9 metabolizes warfarin, and CBD can significantly increase INR, as confirmed by case reports. For cancer patients taking anticoagulants, this poses a particular risk.

Practical rules for minimizing risk

A sensible approach includes four rules:

• inform the oncologist before starting CBD, not after,
• start with low doses (10-20 mg/day) and assess after 2 weeks,
• maintain a minimum 2-hour interval between CBD and oral cytostatics,
• monitor laboratory parameters (blood count, liver enzymes, INR).

In practice, the safest doses are 10-30 mg of CBD per day in the context of oncology. Advertisements encouraging "1,000 mg daily for it to work" have no scientific basis and increase the risk of interactions.

Specific risks in individual chemotherapies

Not all chemotherapy regimens react the same way to CBD. The highest risk of interactions has been described for:

• tamoxifen in breast cancer, where CBD may disrupt metabolism via CYP2D6 and reduce conversion to active endoxifen,
• cyclophosphamide, whose activation requires CYP3A4 inhibited by CBD,
• imatinib in chronic myeloid leukemia, where changes in concentration may affect response,
• paclitaxel and docetaxel, where increased concentrations may exacerbate neuropathy.

For these patients, the decision about CBD should be particularly cautious and supported by measurements of drug concentrations, if possible.

Recommended products in palliative care

For patients seeking sleep support and symptom relief in palliative care, after consulting with an oncologist, practical choices are standardized oils with certification:

• SOOL CBD 5% (500 mg, 10 ml), 76 PLN, low starting dose,
• SOOL CBD 10% (1000 mg, 10 ml), 99 PLN, medium dose,
• Cannova CBG 15% (1500 mg), 240 PLN, support in digestive disorders,
• Mars Dry CBD 9%, 59 PLN, flower exclusively for vaporization, not smoking.

Monitoring response: what to observe?

After incorporating CBD into the routine, it is good to keep a simple symptom diary for 4-6 weeks. Observe: frequency of vomiting, severity of nausea (scale 0-10), amount and quality of sleep, appetite, pain level (NRS 0-10), and quality of life (overall well-being).

If after 2 weeks there is no improvement in any parameter, the dose is likely too low or CBD does not respond to your clinical picture. In consultation with the oncologist, modify the dose or consider other support. Do not increase the dose on your own, especially when undergoing chemotherapy.

What is the current state of research 2024-2026?

In the last two years, over 800 new publications related to cannabinoids and oncology have appeared on PubMed. Most of them are in vitro studies, observational, or reviews. There is still a lack of large randomized phase III studies confirming the impact of CBD or THC on the survival of cancer patients.

Several interesting projects are ongoing.

Current clinical studies

On ClinicalTrials.gov (as of 2026) several dozen protocols with cannabinoids in oncology are active, mainly in the areas of: CINV, cancer pain, cachexia, and quality of life. Only a few check the impact on tumor response, e.g., in glioma (NCT03246113, phase II).

The results of these studies may perhaps update the ASCO guidelines in 2027-2029. For now, full caution remains.

Polish Cancer Registry (PRCN)

National Cancer Registry collects data on incidence and mortality in Poland. In 2022, 170,000 new cases and about 100,000 deaths were recorded. The most common locations are: lung (21,000 new cases/year), breast in women (20,000), prostate in men (18,000), and colon.

Poland has a higher mortality rate than the EU average, partly due to late reporting to doctors. In this context, no “alternative” cannabis therapies can replace prevention and early diagnosis.

What will the next decade bring?

Trend analysis shows that the number of publications is increasing by an average of 12% per year, but the percentage of randomized phase III studies remains low (below 3% of all works). This means that despite media enthusiasm, a solid clinical foundation is still being built slowly.

Probable directions: profiling patients responsive to cannabinoids, nanocapsules increasing bioavailability, and standardization of extracts.

According to National Cancer Registry (2024) in Poland, approximately 170,000 new cases of malignant tumors are registered annually. Active research on ClinicalTrials.gov (2026) mainly concerns symptomatic support, but the guidelines ASCO 2024 remain unchanged: cannabinoids are not recommended as anti-cancer treatment.

Epidemiology: the scale of the cancer problem in Poland and the EU

Cancers are the second leading cause of death in Poland and the EU, surpassed only by cardiovascular diseases. According to European Cancer Information System (2024) approximately 2.7 million new cases of malignant tumors are diagnosed annually across the European Union, with around 1.3 million deaths. Poland maintains a higher mortality rate than the EU average.

This context is crucial for justifying caution towards “alternative” therapies.

The most common cancers in Poland

According to National Cancer Registry (2024) the ranking of incidences is as follows:

• lung cancer, about 21,000 new cases annually, the leading cause of cancer deaths in men,
• breast cancer, about 20,000, the most common cancer in women,
• prostate cancer, about 18,000, the second most common in men,
• colon cancer, about 18,000, in both sexes,
• cancer of the body of the uterus, cervix, ovary, stomach, bladder, kidney.

Pancreatic cancer, although less common (about 3,500 cases annually), remains one of the most lethal, with a 5-year survival rate below 10%. It is precisely with diagnoses of poor prognosis that the temptation to reach for “alternatives” is strongest, and standard oncological therapy is most critical.

Risk factors we can influence

Primary prevention is an area where the evidence is clear. According to World Health Organization (2024) 30-50% of cancers can be prevented by reducing risk factors. The most significant are: tobacco smoking (21% of cancer deaths), alcohol, overweight, low physical activity, low consumption of fruits and vegetables, and infections with HPV, HBV, HCV, Helicobacter pylori.

CBD oil is not a component of cancer prevention. No oncology society recommends it for this purpose. Delaying the cessation of smoking in favor of “taking CBD preventively” is a cognitive shortcut that is harmful.

Sativex and Epidiolex: what does the epilepsy exception mean?

Of all cannabis preparations, only two have received FDA/EMA registration for specific disease indications: Sativex (nabiximols) for spasticity in multiple sclerosis and Epidiolex (CBD) for severe childhood epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis). None of these indications concern cancer.

This is an important counterexample to claims that “CBD cures everything.”

Epidiolex in treatment-resistant epilepsy

Study Devinsky et al. (NEJM 2017) showed that CBD at a dose of 20 mg/kg/day reduces seizure frequency in Dravet syndrome by 39%. Based on this, the FDA approved Epidiolex in 2018. The EMA did the same in 2019.

The case of Epidiolex shows that CBD can be effective in strictly defined indications, at appropriate doses, in a registered pharmaceutical form. This does not automatically mean it helps with cancer, where the pathomechanism is entirely different.

Sativex: spasticity, not cancer

Sativex was registered by the EMA in 2010 for refractory spasticity in MS patients. Its studies in cancer pain, as mentioned Fallon 2018, did not lead to registration for this indication, as endpoints were not achieved.

This again shows that the drug registration process requires hard data, not social media enthusiasm. Lack of registration does not mean uselessness, but it means a lack of evidence sufficient for a health recommendation.

Palliative care and end-of-life: what role can cannabis play?

Palliative care concerns about 40 million people worldwide each year, including 34% with a cancer diagnosis, according to WHO (2024). The goal is not to cure but to improve quality of life: symptom control, dignity, psychological and spiritual support. In this context, cannabinoids have their place.

In Poland, palliative care is funded by the NFZ and provided in stationary, home, and day hospices.

Total pain: the concept of Cicely Saunders

Cicely Saunders, a British pioneer of palliative medicine, introduced the concept of “total pain,” which encompasses physical, emotional, social, and spiritual dimensions. Pain therapy is not just morphine, but also conversation, family support, and psychological care. Cannabinoids can be one of the elements of this mosaic.

In hospice care, some patients report that CBD helps them relax, sleep better, and maintain contact with loved ones in their final months. This is valuable, even if it does not prolong life.

Conversations with family and caregivers

In conversations with caregivers of patients in hospices, the theme of relief recurs when someone authoritatively says, "no, your loved one will not be cured with CBD oil, but yes, it may help them sleep and accept what is coming more peacefully." Honest evidence-based conversation helps more than false hope.

The caregiver has the right to ask the hospice team about every aspect of therapy, including cannabis. A good specialist will respond reliably, without promises of miracles.

Palliative care concerns 40 million people annually, of which 34% have cancer (WHO 2024). Cannabinoids, including CBD and prescription medical marijuana, can support symptom control in selected situations, but their role is not to prolong life, but to improve its quality in advanced disease.

Frequently Asked Questions

Does CBD cure cancer?

No, CBD does not cure cancer. According to National Cancer Institute (2024) and ASCO 2024 no cannabis product has been approved for cancer treatment. Evidence for anti-cancer effects comes from in vitro and mouse studies. Abandoning chemotherapy for CBD may shorten life.

Can I use CBD oil during chemotherapy?

Only after consulting with an oncologist. CBD inhibits CYP3A4 and CYP2C9 enzymes, which metabolize over 300 drugs, including cyclophosphamide, doxorubicin, and paclitaxel (Brown 2019, PMC). Uncontrolled use may increase chemotherapy toxicity. Start with low doses, 10-20 mg/day, and monitor laboratory parameters.

Does CBD help with nausea after chemotherapy?

Yes, but as a second-line option. A review Cochrane 2015 involving 1,326 patients showed the efficacy of cannabinoids in CINV resistant to ondansetron and aprepitant. The FDA has approved dronabinol and nabilone. CBD alone is less studied in this indication than THC-containing preparations.

Are cannabinoids better than morphine for cancer pain?

No, cannabinoids are not a substitute for opioids. Cancer pain affects 55-66% of patients (van den Beuken 2016) and is treated according to the WHO ladder. Cannabinoids, including Sativex in the study Fallon 2018, may play a supportive role in refractory pain, but do not replace morphine or fentanyl.

Can I get medical marijuana by prescription in Poland?

Yes, since November 1, 2017. A prescription can be issued by any doctor, most often a specialist in palliative medicine, neurology, or oncology. The monthly cost of therapy is usually 500-2,000 PLN. According to the Ministry of Health (2024) the number of prescriptions has exceeded 300,000 annually. Medical cannabis flower is standardized, while CBD oils in stores are supplements.

Summary: cannabis in oncology, common-sense principles

Cancer is a disease that requires oncological treatment: chemotherapy, radiotherapy, surgery, and immunotherapy. CBD and cannabis do not cure cancer, and anyone claiming otherwise is disregarding scientific evidence. What cannabis can realistically offer cancer patients is palliative support: alleviating nausea after chemotherapy, relief from opioid-resistant pain, improving appetite, sleep, and quality of life in palliative care. Any such use requires oncologist consent and consideration of drug interactions through CYP3A4 and CYP2C9 enzymes. The guidelines ASCO 2024, the position of NCI and reviews Cochrane consistently indicate: cannabis is an adjunct, not a substitute. Do not abandon chemotherapy. Talk to your oncologist. Make decisions based on data, not on advertisements online.

Author: Michał Waluk. This article is educational and does not replace medical consultation. Therapeutic decisions are made solely by the attending physician.